Ishihara Moe, Hu Junhui, Zhang Xiaoyu, Choi YongHyeon, Wong Anthony, Cano-Ruiz Celine, Zhao Rongwei, Tan Ping, Tso Jonathan L, Wu Lily
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles.
J Vis Exp. 2020 Feb 8(156). doi: 10.3791/60314.
Metastatic clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer. Localized ccRCC has a favorable surgical outcome. However, one third of ccRCC patients will develop metastases to the lung, which is related to a very poor outcome for patients. Unfortunately, no therapy is available for this deadly stage, because the molecular mechanism of metastasis remains unknown. It has been known for 25 years that the loss of function of the von Hippel-Lindau (VHL) tumor suppressor gene is pathognomonic of ccRCC. However, no clinically relevant transgenic mouse model of ccRCC has been generated. The purpose of this protocol is to introduce and compare two newly established animal models for metastatic ccRCC. The first is renal implantation in the mouse model. In our laboratory, the CRISPR gene editing system was utilized to knock out the VHL gene in several RCC cell lines. Orthotopic implantation of heterogeneous ccRCC populations to the renal capsule created novel ccRCC models that develop robust lung metastases in immunocompetent mice. The second model is the chicken chorioallantoic membrane (CAM) system. In comparison to the mouse model, this model is more time, labor, and cost-efficient. This model also supported robust tumor formation and intravasation. Due to the short 10 day period of tumor growth in CAM, no overt metastasis was observed by immunohistochemistry (IHC) in the collected embryo tissues. However, when tumor growth was extended by two weeks in the hatched chicken, micrometastatic ccRCC lesions were observed by IHC in the lungs. These two novel preclinical models will be useful to further study the molecular mechanism behind metastasis, as well as to establish new, patient-derived xenografts (PDXs) toward the development of novel treatments for metastatic ccRCC.
转移性透明细胞肾细胞癌(ccRCC)是肾癌最常见的亚型。局限性ccRCC手术预后良好。然而,三分之一的ccRCC患者会发生肺转移,这与患者的极差预后相关。不幸的是,对于这个致命阶段没有有效的治疗方法,因为转移的分子机制仍然未知。25年来已知,von Hippel-Lindau(VHL)肿瘤抑制基因功能丧失是ccRCC的特征。然而,尚未建立具有临床相关性的ccRCC转基因小鼠模型。本方案的目的是介绍和比较两种新建立的转移性ccRCC动物模型。第一种是小鼠模型中的肾植入。在我们实验室,利用CRISPR基因编辑系统在几种肾癌细胞系中敲除VHL基因。将异质性ccRCC群体原位植入肾包膜,创建了新的ccRCC模型,该模型在免疫活性小鼠中可形成强大的肺转移。第二种模型是鸡胚绒毛尿囊膜(CAM)系统。与小鼠模型相比,该模型更节省时间、人力和成本。该模型也支持强大的肿瘤形成和血管内侵入。由于CAM中肿瘤生长周期仅10天,在收集的胚胎组织中通过免疫组织化学(IHC)未观察到明显转移。然而,当在孵化出的鸡中肿瘤生长延长两周时,通过IHC在肺中观察到微转移性ccRCC病变。这两种新的临床前模型将有助于进一步研究转移背后的分子机制,并建立新的患者来源异种移植(PDX),以开发针对转移性ccRCC的新疗法。